




Contents lists available at [ScienceDirect](http://www.sciencedirect.com)

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtb



Original article <http://dx.doi.org/10.1016/j.apjtb.2017.07.018>

Direct detection of *rpoB* and *katG* gene mutations of *Mycobacterium tuberculosis* in clinical samples



Sunil Pandey^{1,*}, Ashima Lamichhane¹, Anu Byanjankar¹, Ansuma Kharel¹, Chandrakala Rai¹, Sunil Prasad Lekhak³, Menuka Karki⁴

¹Department of Medical Microbiology, Nobel College, Pokhara University, Nepal

²Department of Biological Sciences, Eastern Illinois University, USA

³Decode Genomics and Research Center, Sinamangal, Kathmandu, Nepal

⁴Department of Cell Biology, New Mexico State University, USA

ARTICLE INFO

Article history:

Received 28 Nov 2016

Received in revised form 21 Jun 2017

Accepted 26 Jul 2017

Available online 12 Aug 2017

Keywords:

Mycobacterium tuberculosis

Direct detection

rpoB

katG

Mutation

Nepal

ABSTRACT

Objectives: To study the *rpoB* and *katG* gene mutation rate and its markers.

Methods: Cross-sectional study methods were used to study Tuberculosis. A total of 45 sputum samples were collected from Annapurna Neurological Institute and Allied sciences. Then, acid fast bacilli staining were performed. Positive and negative samples were carried for conventional polymerase chain reaction identification and electrophoresis.

Results: Out of 45 samples, 3 were acid fast bacilli positive and the rest were negative. Male participants were more as compare to female participants and the mutation in *rpoB* and *katG* gene was found similar *i.e.* 6.66% among the total samples.

Conclusions: We can conclude that genetic mutation in *Mycobacterium tuberculosis* can be identified directly from the clinical samples. However, we have carried this study in less sample size and to validate research on large number of sample is recommended.

1. Introduction

Tuberculosis (TB) is caused by bacteria *Mycobacterium tuberculosis*, which most affects the lung and is preventable and curable. In 2015, there were an estimated 10.4 million new (incident) TB cases worldwide, of which 5.9 million (56%) were among men, 3.5 million (34%) among women and 1.0 million (10%) among children [1]. In 2015, there were a predictable 480 000 incidences of multidrug-resistant TB (MDR-TB) and

a supplementary 100 000 people with rifampicin-resistant TB (RR-TB) who were also newly eligible for MDR-TB treatment [1]. Many social & economic factors including poverty, drug addiction and lack of health care facilities are compounding factors for causation of tuberculosis [2,3]. Isoniazid and rifampicin are the antibiotics advised first-line drugs and are the first medicines used to treat all persons with TB disease. Although there are advances in TB therapy over the past century, there were an estimated nine million new cases and 1.1 million deaths in 2013 [4].

Usually drug resistance occurs when bacteria become resistant to the drugs which are used to treat TB. It means that the drug no longer can kill the pathogens of TB. The most important way to measure the TB is quickly diagnosis with recommendation, treatment guidelines, monitoring the patients report frequently and full completion of the therapy. Isoniazid resistance (INH-R) is more complex and is related with mutations in one or more genes, such as the genes encoding catalase-peroxidase [*katG* gene (codon 315)] and the enoyl-acyl-carrier protein reeducates enzyme, which is involved in mycolic acid biosynthesis [*inhA*

*Corresponding author: Sunil Pandey, Department of Medical Microbiology, Nobel College, Pokhara University, Nepal.

Tel: +13853689341

E-mails: pandeysunil347@gmail.com, spandey@eiu.edu (S. Pandey).

Foundation project: This research is supported and funded by Department of Medical Microbiology, Nobel College, Pokhara University, Kathmandu Nepal with grant number MM-124.

The study protocol was performed according to the Helsinki declaration and approved by Institutional Review Committee of Nepal Health Research Council. Informed written consent was obtained from patients.

Peer review under responsibility of Hainan Medical University. The journal implements double-blind peer review practiced by specially invited international editorial board members.

(–15 nucleotide)] [5,6]. The prevalence of the *katG* (AGC-ACC) mutation among MDR-MTB strains in the world varies, being low in area with low TB incidence and high in area with high TB incidence [7,8]. Most INH-resistant clinical isolates become resistant by losing or altering *katG* activity, nevertheless, only *katG* mutations do not result in all observed INH resistance [7–10].

Due to lack of chronic and infectious disease management policies, diseases such as tuberculosis, cancer, diabetes and cardiovascular disease do not fall under government priorities in Nepal. Direct detection of mutated genes of *Mycobacterium tuberculosis* from clinical specimen is rare in Nepal as there are only few researches carried out to detect *rpoB* and *KatG* gene mutations in MTB from clinical isolates. This led us develop this research so that we can understand the current level of mutation of *rpoB* & *katG* gene from direct sample in Nepal and help in screening and treatment. Tuberculosis is one of the greatest widespread infectious diseases in Nepal and have a serious threat to the health and growth of the people of this country [10,11]. In Nepal, about 60% of adults and 45% of the overall population have been infected with TB. Nearly 2% of people are ill every year [11].

Many developing and sub-Saharan countries are heavily burdened with MDR-TB disease and cases of resistant strains to first line drugs are increasing [12]. However, routine diagnostic tests do not type to strain level and this has complicated management of MDR-TB patients. Previously, no direct detection of *rpoB* and *katG* gene study in Nepal has determined the strains in human MDR-TB isolates. But this type of study gives great value to TB patients in proper diagnosis of the diseases.

2. Materials and methods

2.1. Study setting

The study was carried out in Decode Genomics and Research Center Pvt. Ltd., Sinamangal Kathmandu, Nepal. The hospital was chosen because of large number of visit of tuberculosis patients as according to hospital research laboratory record. Ethical approval from patients, hospital and Nepal Health Research Council was taken. Hospitalized patients of both sexes were included in the study.

2.2. Sample size

We collected sample at least 45 patients visiting the hospital. This is a cross-sectional study and the sample about this size will be sufficient to identify the *rpoB* & *katG* gene mutation from clinical samples.

2.3. Sample collection

In total, 45 samples were collected from Annapurna Neurological Institute of Allied Sciences from Kathmandu, Nepal. Sputum of hospitalized patient was taken as study sample. Spot and early morning samples of sputum were collected in 2 sterile wide mouth containers and were processed and graded on the same day as per National Tuberculosis Control Programme (NTCP) guidelines. Only sputum samples were included in the study and the volume was 5 mL or more. Samples were labeled as saliva mucoid, purulent, mucopurulent or blood stained according to their physical appearance.

2.4. Sample handling and DNA extraction

Collected sample was first decontaminated by Petroff's modified method (Table 1), and Acid Fast Bacilli (AFB) staining was carried out. Both positive and negative AFB results were processed for DNA extraction. Collected patient's sputum samples were vortexed and decontaminated by Modified Petroff's method. Four mL of the decontaminated sputum were homogenized for 15 min in a shaker using an equal volume of 4% NaOH because modified Petroff's method is an excellent simplified decontamination technique. After 15 min, centrifugation at 3000 rpm, the deposit was neutralized with 20 mL of sterile distilled water. The samples were again centrifuged at 3000 rpm for 15 min [13]. From the pellet, DNA was extracted which was processed for polymerase chain reaction (PCR) for the detection of TB using *MPB64* and *IS6110* primers. Gel Electrophoresis was performed to detect the PCR amplification product.

2.5. Primers amplification conditions

The compositions of reaction mixtures and PCR conditions for each of three different *rpoB* codons and *katG*315 codon were as described by [14], with few modifications. For *rpoB* MAS-PCR each 25- μ L reaction mixture contained purified DNA sample (0.5 μ L), $MgCl_2$ (2.5 mM for *rpoB*526- and *rpoB*531-PCR or 1.5 mM for *rpoB*516- PCR), 1 U of recombinant *Taq* DNA polymerase (Solis Borden, Estonia). The reactions of *rpoB*526-PCR and *rpoB*531-PCR were performed in different condition as attached in Table 1.

3. Results

Of the 45 samples collected, 60% were from the male patients and 40% were from the female patients. Most cases of

Table 1

Master Mix final concentration, PCR condition used in MTB, *rpoB* and *katG* genes.

Genes	Master mix component				PCR condition				
	Master mix	DNA	Primers	Distilled water	Initial denaturation	Denaturation	Annealing	Elongation	Final elongation
MTB	12.5 μ L	0.5 μ L	<i>IS6110</i> , FP(10 pmol/ μ L) ⁻¹ RP(10 pmol/ μ L) ⁻¹	9 μ L	95 °C for 5 min	94 °C for 50 s	56 °C for 45 s	72 °C for 1 min	72 °C for 2 min
<i>rpoB</i>	12.5 μ L	0.5 μ L	OR(10 pmol/ μ L) ⁻¹ OF(10 pmol/ μ L) ⁻¹ IF(10 pmol/ μ L) ⁻¹	9 μ L	96 °C for 5 min	94 °C for 50 s	65 °C for 50 s	72 °C for 1 min	72 °C for 3 min
<i>katG</i>	10 μ L	1 μ L	OF(10 pmol/ μ L) ⁻¹ OR(10 pmol/ μ L) ⁻¹ IR(10 pmol/ μ L) ⁻¹	11 μ L	96 °C for 5 min	95 °C for 1 min	66 °C for 40 s	72 °C for 1 min	72 °C for 3 min

Final volume of 25 μ L; Cycle 25.

TB were isolated between the age group of 21–71 years, of which 28.88% were new cases and 71.11% were retreated cases. Of the total samples, 6 of them were found to be AFB positive and 39 were AFB negative.

However, the Gel Electrophoresis of PCR product showed TB positive for 31 (68.88%) samples and negative for 14 (31.11%) samples determined by the presence of bands of *MPB64* and *IS6110*. Similarly, of the total samples three samples had *rpoB* gene mutation, three had *katG* gene mutation and one had both *rpoB* and *KatG* gene mutation.

4. Discussion

Lack of education among Nepalese might be one of the great reasons for people presenting advance stage of disease in Nepal and in developing countries. Many of the people are less aware of their health and method of infectious disease prevention.

In our study, we found 60% cases were males and 40% were females. Most cases of TB were in the age group of 21–56 years. Furthermore, 6 sample was found to be AFB positive 39 were found to be negative with new and retreated cases with 13 (28.88%) and 32 (71.11%), respectively. Moreover, *rpoB* mutation was found in 3 patients (6.66%) and *katG* gene mutation was also found in 3 patients (6.66%) of total sample. One sample shows both *katG* and *rpoB* gene mutation.

In world scenario of TB cases, smear microscopy has long been known as the primary method for screening of TB, with a case detection rate of not more than 68%. Considerable advancement has been made in the last few years to resolve the basis of resistance against INH and RIF. These are the major challenges facing control and treatment programme worldwide [3,4,15–18]. Large epidemics have been associated with *Mycobacterium tuberculosis* drug resistant strains [19–23].

This identification is likely to provide a regime for anti-tuberculosis treatment. The determination of resistant genes will be helpful for clinicians to identify the most appropriate antibiotics suitable for the treatment of the patients also. The information gained from this study will be useful for health educators, and health care providers in developing specific pragmatic education.

The main aim of this study was to directly detect the *rpoB* & *katG* gene mutations from clinical samples in Nepal. This prospective cross-sectional study was conducted at Decode genomics and research center Pvt. Ltd., Sinamangal, Kathmandu, Nepal and sample with their epidemiological data are brought from Annapurna Neurological Hospital and Allied sciences to determine the prevalence rate of MTB and MDR TB among the hospital admitted patients. Early morning Sputum sample was collected from the infected patients of Annapurna Neurological Institute of Allied Sciences. Then, it was examined by standard microbiological procedures and molecular methods (PCR). In our study, 6 samples were found to be AFB positive. DNA was extracted from all samples using Promega kit following standard protocol. DNA was processed for polymerase chain reaction for detection of TB by *MPB64* and *IS6110* by using outer forward and outer reverse primer respectively. TB-PCR was found to be positive for 31 (68.88%) samples and 14 (31.11%) samples were found negative.

We have now come to comprehend that drug-resistant TB is not a conceivable scenario by taking different antibiotics to decrease. Furthermore, from direct clinical samples, mutation can be detected; however, this type of practice has not been

practiced so far in Nepal. This is even reliable when result need to disseminate fast for treatment. Nevertheless, large sample size might be needed to validate this finding.

Acknowledgement

We want to acknowledge Nobel College, Pokhara University Medical Microbiology Department for financial support for this study and Decode Genomics and Research Center for providing us molecular techniques needed in this study.

Conflict of interest statement

We declare we don't have competing of interest.

References

- [1] World Health Organization. *Global tuberculosis report*. Geneva: WHO; 2016. [Online] Available from: <http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394eng.pdf?ua=1> [Accessed on 3rd January 2017]
- [2] Millet JP, Moreno A, Fina L, Del Baño L, Orcau A, de Olalla PG, et al. Factors that influence current tuberculosis epidemiology. *Eur Spine J* 2013; **22**(4): 539–48.
- [3] Rylance J, Pai M, Lienhardt C, Garner P. Priorities for tuberculosis research: a systematic review. *Lancet Infect Dis* 2010; **10**(12): 886–92.
- [4] World Health Organization. *Global tuberculosis report*. Geneva: WHO; 2014 [Online] Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf [Accessed on 5th April 2016].
- [5] Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. *Lancet* 2013; **379**(9829): 1902–13.
- [6] Migliori GB, Lodenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? *Eur Respir J* 2013; **29**(3): 423–7.
- [7] Bang H, Park S, Hwang J, Jin H, Cho E, Kim DY, et al. Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR. *J Med Microbiol* 2011; **60**(10): 1447–54.
- [8] Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in *Mycobacterium tuberculosis*: a systematic review. *PLoS One* 2015; **10**(3): e0119628.
- [9] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of *Mycobacterium tuberculosis* from Northwestern Russia: implications for genotypic resistance testing. *J Clin Microbiol* 2002; **40**(10): 3810–3.
- [10] Sandhu GK. Tuberculosis: current situation, challenges and overview of its control programs in India. *J Glob Infect Dis* 2011; **3**(2): 143.
- [11] National Tuberculosis Programme Nepal. *Tuberculosis annual report*. Bhaktapur: National Tuberculosis Centre, Department of Health Services, Ministry of Health & Population, Government of Nepal; 2014–2015. [Online] Available from: http://www.nepalntp.gov.np/theme/images/uploads/NTP_Annual_Report_2070-71_final.pdf [Accessed on 5th April 2016]
- [12] Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al., editors. *Disease control priorities in developing countries*. New York: Oxford University Press; 2006.
- [13] Tripathi K, Tripathi PC, Nema S, Shrivastava AK, Dwiwedi K, Dhanvijay AK. Modified Petroff's method: an excellent simplified decontamination technique in comparison with Petroff's method. *Int J Recent Trends Sci Tech* 2014; **1**(10): 461–4.
- [14] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Allele-specific *rpoB* PCR assays for detection of rifampin-resistant

- Mycobacterium tuberculosis* in sputum smears. *Antimicrob Agent Chemother* 2003; **47**(7): 2231-5.
- [15] Mansoer J, Scheele S, Floyd K, Dye C, Sitienei J, Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. *Bull World Health Org* 2009; **87**(3): 186-92.
- [16] Sreevatsan S, Pan X, Zhang Y, Deretic V, Musser JM. Analysis of the *oxyR-ahpC* region in isoniazid-resistant and-susceptible *Mycobacterium tuberculosis* complex organisms recovered from diseased humans and animals in diverse localities. *Antimicrob Agents Chemother* 1997; **41**(3): 600-6.
- [17] Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of *Mycobacterium tuberculosis*. *J Clin Microb* 2006; **44**(12): 4498-510.
- [18] Watterson SA, Wilson SM, Yates MD, Drobniowski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in *Mycobacterium tuberculosis*. *J Clin Microbiol* 1998; **36**(7): 1969-73.
- [19] Ang CF, Cajucom MAM, Kim Y, Bang H, Lee H, Cho SN, et al. Evaluation of a rapid assay for identification of *Mycobacterium tuberculosis* grown in solid and liquid media. *Int J Tuberc Lung Dis* 2011; **15**(11): 1475-8.
- [20] Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, Van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. *Lancet* 2010; **375**(9728): 1830-43.
- [21] Stanley RE, Blaha G, Grodzicki RL, Strickler MD, Steitz TA. The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. *Nat Struct Mol Boil* 2010; **17**(3): 289-93.
- [22] Bhatt CP, Bhatt AB, Shrestha B. Molecular characterization and comparison of multi drug resistant strains of *Mycobacterium tuberculosis* by phenotypic and genotypic method. *SAARC J Tuberc Lung Dis HIV/AIDS* 2011; **8**(2): 17-22.
- [23] Gupta A, Prakash P, Singh SK, Anupurba S. Rapid genotypic detection of *rpoB* and *katG* gene mutations in *Mycobacterium tuberculosis* clinical isolates from Northern India as determined by MAS-PCR. *J Clin Lab Anal* 2013; **27**(1): 31-7.